Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

European Research Council grant · Running

MetaBoost MetaBoost: Metabolic Reprogramming for Neuronal Differentiation

Coordinator
Universidade Nova De Lisboa, Portugal
Runs
1 September 2026 to 29 February 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101248627

What the project is doing

In the project's own words, from its summary on CORDIS.

The transition from glycolytic to oxidative phosphorylation (OxPhos) metabolism is crucial for proper neuronal differentiation and maturation, a key process in generating functional neurons essential for advancing neuroscience research and therapeutic applications. However, commercially available media to generate neurons often overlook this key metabolic transition. MetaBoost aims to fill this gap by developing an innovative, easy-to-use, universally compatible media supplement that induces metabolic reprogramming in Drosophila or human neural cells, enhancing differentiation and maturation efficiently and reproducibly.

Building on the success of MetaBoost2Fly, developed during the ERC Starting Grant StemCellHabitat to address unmet needs in fly model-based neuroscience research, this Proof of Concept (PoC) aims to: 1.Validate MetaBoost2Fly for Drosophila cells, advancing from Technology Readiness Level (TRL) 3 to 4, refining its formulation, assessing reproducibility, and exploring commercial potential for the Drosophila research community.2.Establish MetaBoost2Human (targeting TRL3), a media supplement designed to shift metabolism from glycolysis to OxPhos in human induced pluripotent stem cells (hiPSCs) and neural stem cells (NSCs), enhancing neuronal differentiation and maturation.

MetaBoost has the potential to transform the cell culture market, addressing the needs of academia, pharma, and biotech in neuroscience research, drug discovery, and preclinical development. Additionally, MetaBoost supports the shift to human cell models over animal studies, aligning with the 3Rs principle (Replacement, Reduction, Refinement), promoting more ethical, relevant research. Finally, MetaBoost2Fly and MetaBoost2Human are positioned as commercially viable ""Research Grade"" products, offering rapid market entry and strong potential to accelerate neuroscience innovation""

Who is involved

OrganisationCityCountryRole
Universidade Nova De LisboaLisboaPortugalCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI